CagriSema — Metabolic & Weight Loss Deep Research

Published · Researched 2026-09-21

Slug: cagrisema · Category: Metabolic & Weight Loss · File version: 2026-09-20 (text)

1. Overview

Maker: Novo Nordisk (Bagsværd, Denmark). What it is: CagriSema is Novo Nordisk's investigational once-weekly subcutaneous fixed-dose combination of cagrilintide 2.4 mg (long-acting amylin analogue) plus semaglutide 2.4 mg (GLP-1 receptor agonist), developed for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Status as of September 2026: Still investigational — NOT approved by FDA or EMA. Novo Nordisk submitted a New Drug Application (NDA) to the FDA in December 2025, with an FDA decision expected in late 2026 (reported by Drug Topics, Feb 2026; NDA filing reported by Patient Care Online). The global phase 3 REDEFINE programme is the evidence base:

• REDEFINE 1 (n=3,417; 68 weeks; obesity, no diabetes): headline results 20 December 2024. CagriSema met its primary endpoint (superior to placebo): 22.7% mean weight loss under the trial-product estimand (vs 11.8% cagrilintide alone, 16.1% semaglutide alone, 2.3% placebo) and 20.4% under the treatment-policy estimand. 40.4% of CagriSema participants lost ≥25% body weight. Only 57.3% of the CagriSema arm were on the highest dose at week 68 (flexible dosing protocol). (Source: Novo Nordisk company announcement, 20 Dec 2024.)
• REDEFINE 2 (n≈1,200; 68 weeks; overweight/obesity with type 2 diabetes): announced March 2025 — 15.7% weight loss at 68 weeks (secondary reporting; ECHEMI/Reuters coverage).
• REDEFINE 4 (n=809; 84 weeks; open-label head-to-head vs tirzepatide 15 mg): headline results 23 February 2026. CagriSema did not meet its primary endpoint of non-inferiority: 23.0% vs 25.5% with tirzepatide (efficacy estimand); 20.2% vs 23.6% (treatment-regimen estimand). Safety/tolerability consistent with the GLP-1 class. Novo announced it is exploring higher-dose CagriSema combinations in additional trials. (Sources: Novo Nordisk press release via BioSpace/GlobeNewswire, 23 Feb 2026.)
• REDEFINE 5 (n=331; 68 weeks; Japan and Taiwan; CagriSema vs semaglutide 2.4 mg): 18.4% vs 11.9% mean weight loss (ETD −6.5 pp, p<0.0001); 95.4% achieved ≥5% loss. Presented at ObesityWeek, Nov 2025; published in The Lancet Diabetes & Endocrinology. (Sources: Novo Nordisk ScienceHub slide deck; Lancet abstract.)
• REDEFINE 3 (cardiovascular outcomes, ~7,000 participants) and REDEFINE 11 (readout pending as of Feb 2026) are ongoing/other programme elements per Novo statements.

2. Social standing — platform pulse

Overall pulse: CagriSema is framed across the social layer as the most anticipated combo in the obesity pipeline — Novo's amylin + GLP-1 answer to Lilly's tirzepatide — but the 2024–2026 readouts landed as a two-act disappointment story: REDEFINE 1's 22.7% fell short of the ~25% whisper number, and REDEFINE 4's non-inferiority miss against tirzepatide in Feb 2026 cemented the "great drug, wrong race" narrative.

Threads (primary social layer):

• @dr.purplehwi (Korean endocrinologist, Threads, Feb 2026): long post on the REDEFINE-4 readout — CagriSema 23% at 84 weeks vs tirzepatide 25.5%, non-inferiority not demonstrated, Novo's stock fell sharply in European trading while Lilly's rose. Her takeaway: 23% is clinically meaningful, "but the market wasn't waiting for 'meaningful,' it was waiting for proof of superiority… the GLP-1 + amylin combination can hardly be called a failure." (Paraphrased; post in Korean, ~16 likes, 5 replies.)
• @peptidou.jp (Japanese peptide-info account, Threads, 19 Sep 2026): pushed back on the "failed drug" framing using REDEFINE-5 data — 18.4% loss at 68 weeks in the Japan/Taiwan trial vs 11.9% with semaglutide alone, verified against the publication and ClinicalTrials.gov — arguing global verdicts and country-level data should be read separately. Links to peptidou.jp news page (2026-09-16). (Paraphrased from Japanese.)
• @loveataya16 (Threads, May 2026, Malay-language): self-reported gray-market stack — after plateauing on retatrutide, added "cagrisema" and reported dropping from 84 kg to 79 kg in ~2 weeks with appetite/cravings ("food noise") fully suppressed, but notable moodiness without sugar intake. Self-report, UNVERIFIED; illustrates how the gray market already sells "cagrisema" blends and users stack them with retatrutide.
• @berry.matcha26 (Threads, Aug 2026): "CagriSema tu apa ye?" ("What is CagriSema?") — 8 replies — showing the name is now circulating as a curiosity item in Southeast Asian GLP-1 chatter.

Facebook Groups (highest-signal layer — gap): Searched public groups via facebook-cli for "cagrisema", "cagrilintide", and "amylin" (role=any): no dedicated CagriSema groups and no matching posts found. Broader "peptide" searches surfaced only general groups ("Peptides - information. Education. and sharing" ~1,000 members; "Peptide Community 101" ~878 members); targeted post queries for "cagrisema"/"cagrilintide" inside them returned zero results. The community conversation about CagriSema on Facebook, if it exists, lives in private/closed groups not visible to this search.

Instagram: No CagriSema content found in the authenticated account's saved posts (19 saved posts scanned; none matching cagrisema/cagrilintide/amylin). social.search for cross-platform IG/Threads/FB content timed out twice — recorded as a tool gap, not as absence of content.

Group consensus (from visible sources): Anticipation → disappointment arc. Praise centers on the mechanism story (two complementary satiety pathways, 22.7% near-best-in-class efficacy, 40.4% hitting ≥25% loss). Complaints center on: (a) REDEFINE 1 missing the ~25% expectation set by pre-readout speculation; (b) the flexible-dosing protocol leaving only 57.3% on max dose, fueling "the trial under-dosed it" arguments; (c) the REDEFINE-4 head-to-head loss to tirzepatide; (d) GI side effects consistent with the class.

Viral moments: (1) 20 Dec 2024 — REDEFINE-1 readout; Novo shares fell sharply on the "only" 22.7% figure. (2) 23 Feb 2026 — REDEFINE-4 non-inferiority miss; Novo stock dropped again, Lilly's rose; clinician Threads/LinkedIn commentary framed it as "meaningful but not superior."

3. Social validation — Tier 3 (weak)

Tier: Tier 3 — single platform, flag weak. Evidence comes from Threads (4 distinct posts, including a clinician and a Japan-focused research account) plus secondary web commentary (peptide guide on GitHub citing r/loseit and r/PeptideScience anticipation; clinician blogs). Facebook Groups returned zero hits for all CagriSema-related keywords, and no Instagram owner content was found (account saved-posts scan + social.search timeouts). The social layer therefore does not meet the two-of-three bar; treat community depth as thin.

Named sources and what each proves:

• Threads @dr.purplehwi (endocrinology physician, Feb 2026) — proves the clinician-side "disappointment vs expectations" framing of REDEFINE-4 exists in the wild, with market-reaction context.
• Threads @peptidou.jp (19 Sep 2026) — proves REDEFINE-5's Japan/Taiwan data is circulating as a counter-narrative to the "CagriSema failed" take; independently cites the Lancet publication and ClinicalTrials.gov.
• Threads @loveataya16 (May 2026) — proves gray-market "cagrisema" vials/blends are being bought and stacked with retatrutide by end users; anecdotal efficacy/ side-effect self-report only.
• Threads @berry.matcha26 (Aug 2026) — proves name-level awareness spreading in SE Asian GLP-1 chatter.
• Facebook public group search (Sep 2026) — proves absence: no public CagriSema groups or posts surfaced; the highest-signal layer is currently a gap for this item.
• GitHub peptide guide (palindsay/peptide_research, Peptide_Guide_V8.md) — secondary source noting r/loseit and r/PeptideScience anticipation of the FDA filing and that "CagriSema vs. tirzepatide" is the dominant comparison; proves Reddit-side interest exists, but was not directly observed in this session.
• Vendor product pages (peptidesskin.com, simplepeptide.com, alphaomegapeptide.com, purepharma.ph, peptideshop.online) — prove gray-market availability of "CagriSema" research blends; vendor marketing claims (purity, COAs) are UNVERIFIED.

4. Key specs

5. Pricing (dated)

• Brand MSRP: None — investigational; no approved product, no pharmacy price exists.
• Gray-market "research blend" prices (all observed 2026-09-20 via web search; page crawl dates vary, prices not independently confirmed):
  • peptidesskin.com — CagriSema (Cagrilintide + Semaglutide) blend, 10 mg & 20 mg sizes, $69.00 USD (page listed "$69.00 USD", Research Use Only).
  • simplepeptide.com — CagriSema 10MG/10MG, $124.60 (sale; was $178.00), RUO.
  • alphaomegapeptide.com — CagriSema 10MG/10MG, $185.00/vial; bulk $175.75 (5–9) / $162.80 (10+), RUO.
  • purepharma.ph — CagriSema 2.5 mg + 2.5 mg/vial, $95.00, 26 in stock shown.
  • peptideshop.online — CagriSema 5 mg, $240.00/kit of 10 vials (i.e. ~$24/vial at that listing), purity claimed ≥98%, reship/resend guarantee advertised.
  • Independent peptide guide (GitHub, palindsay/peptide_research) cites a $8–$25/mg street range for cagrilintide research vials.
• Marketplace used range: None observed — facebook-cli marketplace search -q "cagrisema" (2026-09-20) returned zero listings. Peptide listings are routinely removed from Facebook Marketplace; absence here is expected, not evidence of no secondary market.
• Note: Gray-market "CagriSema" vials are unregulated research chemicals of uncertain content/purity; prices reflect what vendors claim to sell, not a verified product. Substitution: several vendors also sell cagrilintide and semaglutide as separate vials for user-side "stacking" — noted openly where seen (e.g., dosing-protocol sites describe stacked protocols).

6. What is included / what else is needed

• Included (gray-market vendor format): Lyophilized (freeze-dried) powder in a sealed vial, labeled as a cagrilintide + semaglutide blend (typical sizes 5 mg, 10 mg, or 10MG/10MG per vendor). Some vendors advertise a Certificate of Analysis (COA) per batch — vendor claim, UNVERIFIED.
• Needed for use (per gray-market/vendor and community guidance, not medical advice): bacteriostatic water for reconstitution, sterile syringes/needles, alcohol swabs; refrigeration at 2–8 °C after reconstitution (community/vendor guidance cites ~28-day use window with bacteriostatic water; plain sterile water has no preservative — treat per supplier insert). Do not freeze reconstituted vials. Nothing here is dosing guidance — there is no approved dosing for any gray-market vial.
• Needed for the real product: an FDA/EMA approval (pending; decision expected late 2026), a prescription, and the approved delivery device — none exist yet.

7. Support reality

• Manufacturer support: None available to consumers — the product is investigational and unapproved; Novo Nordisk offers no patient support, warranty, or returns channel for CagriSema.
• Gray-market vendor support: Varies by vendor and is effectively unenforceable. Example: peptideshop.online advertises refunds/resends for quality, customs, or delivery failures — a marketing claim, UNVERIFIED by community reports in this session. No community reports on vendor support quality for CagriSema specifically were found.
• Community support: Thin — no dedicated public Facebook groups or owner communities found (see §3). Discussion is scattered across Threads posts, Reddit (per secondary guide), and clinician blogs.

8. Community verdict

CagriSema carries the strongest mechanism story in the late-stage obesity pipeline — amylin plus GLP-1 produced the best phase 3 weight-loss figures short of tirzepatide — but the visible community has already priced in disappointment after two readouts missed the ~25% hype number and the head-to-head loss to tirzepatide. With the FDA decision expected late 2026 and higher-dose trials in motion, the honest read is: a genuinely potent investigational combo whose commercial narrative now depends on regulators and next-generation dosing, while the gray market is already selling unregulated "CagriSema" blends of unknown content.

9. Regulatory & safety status (plain language)

• Not approved. CagriSema is investigational — it is NOT approved by the FDA, EMA, or any other regulator as of September 2026. An FDA application was filed in December 2025 with a decision expected late 2026; approval is not guaranteed.
• Any vial sold online is a research chemical. Products labeled "CagriSema" on peptide vendor sites are unregulated research chemicals "not for human use." Their actual contents, purity, sterility, and dose accuracy are unknown and unverified. Using them as medicine is illegal in many jurisdictions and carries real health risks (incorrect dosing, contamination, unknown excipients).
• Known safety signals (from trials of the real product): mostly gastrointestinal side effects — nausea, vomiting, diarrhea — typically mild to moderate and fading over time; the overall profile was described as consistent with the GLP-1 drug class. Trial participants were medically screened and monitored — none of that applies to gray-market use.
• Bottom line: there is currently no legal, regulated way to obtain CagriSema as a medicine.

10. Missing-image views + UNVERIFIED points log

Image views (no approved brand product exists; vendor vial photos are the real photography layer): Sourcing attempted 2026-09-20 via image-search across 5 queries ("cagrisema vial", "cagrisema peptide bottle", "cagrisema unboxing review vial", "cagrilintide vial photo", "cagrisema kit box vials"); ~30 candidate URLs found, 7 downloaded and visually inspected. Result: 0 real photographs exist. Every CagriSema-labeled image found is a vendor CGI/marketing render (peptidesskin.com, tk-peptides.com, propharmapeptides.com, nextlevelpharm.com, peptidesmaxxing.com, ascend-nutrition.com) — all rejected under the zero-synthetic-image policy. No owner-in-use, unboxing, scale, or box photos were found anywhere. All 8 views honestly missing:

• hero — MISSING (no real photo exists)
• side — MISSING (no real photo exists)
• rear — MISSING (no real photo exists)
• top (alternate angle) — MISSING (no real photo exists)
• detail — MISSING (no real photo exists)
• owner-in-use — MISSING (no real photo exists)
• scale — MISSING (no real photo exists)
• box/accessories — MISSING (no real photo exists)

Recommendation: revisit after FDA approval (expected late 2026), when a real branded product with real photography will exist.

UNVERIFIED points:

1. All gray-market prices above — observed 2026-09-20 via search-result pages; not confirmed on live vendor checkout, and vendor purity/COA claims are marketing, not independent verification.
2. The Malay Threads self-report (@loveataya16) of weight loss and side effects from a gray-market "cagrisema" + retatrutide stack — anecdote, self-reported, no verification of what was actually injected.
3. Dosing/titration tables on gray-market protocol sites (e.g., peptidedosingprotocols.com) — not clinical guidance; REDEFINE protocol details for phase 3 flexible dosing beyond the 57.3%-on-max-dose figure were not independently pulled from the NEJM publication in this session.
4. "Most anticipated combo" / Reddit anticipation framing — qualitative social pulse; no engagement numbers were fabricated or cited. The r/loseit and r/PeptideScience mentions come via a secondary GitHub guide, not direct observation.
5. Timing of REDEFINE-11 readout and the higher-dose CagriSema trial — announced by Novo (Feb 2026) as upcoming; no results yet.
6. Exact translation/paraphrase fidelity of the Korean (@dr.purplehwi) and Japanese (@peptidou.jp) Threads posts — summarized from machine-readable text, not professional translation.
7. social.search timed out twice — cross-platform IG/FB/Threads social content beyond the CLI results could not be assessed in this session.

Not medical advice. This is research material only; consult a qualified clinician.

Named sources

• Threads @dr.purplehwi (endocrinology physician, Feb 2026) — proves the clinician-side "disappointment vs expectations" framing of REDEFINE-4 exists in the wild, with market-reaction context. (Feb 2026)
• Threads @peptidou.jp (19 Sep 2026) — proves REDEFINE-5's Japan/Taiwan data is circulating as a counter-narrative to the "CagriSema failed" take (Sep 2026)
• Threads @loveataya16 (May 2026) — proves gray-market "cagrisema" vials/blends are being bought and stacked with retatrutide by end users (May 2026)
• Threads @berry.matcha26 (Aug 2026) — proves name-level awareness spreading in SE Asian GLP-1 chatter. (Aug 2026)
• Facebook public group search (Sep 2026) — proves absence: no public CagriSema groups or posts surfaced (Sep 2026)
• GitHub peptide guide (palindsay/peptide_research, Peptide_Guide_V8.md) — secondary source noting r/loseit and r/PeptideScience anticipation of the FDA filing and that "CagriSema vs. tirzepatide" is the dominant comparison
• Vendor product pages (peptidesskin.com, simplepeptide.com, alphaomegapeptide.com, purepharma.ph, peptideshop.online) — prove gray-market availability of "CagriSema" research blends
• Springer Clinical Pharmacokinetics review — Mechanism: Fixed-dose combination: **cagrilintide** (long-acting amylin analogue; activates amylin/calcitonin receptors incl.
• Novo Nordisk announcements — Safety signals: Most common AEs: **gastrointestinal** (nausea, vomiting, diarrhea); mostly mild-to-moderate, diminishing over time; consistent with GLP-1 class. (Dec 2024)
• Springer article 10.1007/s40262-026-01654-0 — Half-life: Cagrilintide: terminal elimination half-life ≈ **180 h (~7.5 days)**; semaglutide: ≈ **1 week**. (2021)
• MDedge/Medscape phase 2 reporting — Dosing schedule: **Once-weekly subcutaneous injection.** Trial titration: 0.25 → 0.5 → 1.0 → 1.7 mg of each component every 4 weeks, reaching maintenance **2.4 mg + 2.4 mg at week 16**.
• Novo Nordisk REDEFINE-1 announcement — Dosing schedule: **Once-weekly subcutaneous injection.** Trial titration: 0.25 → 0.5 → 1.0 → 1.7 mg of each component every 4 weeks, reaching maintenance **2.4 mg + 2.4 mg at week 16**.
• Novo Nordisk — Administration route: Subcutaneous injection (investigational fixed-dose combo pen in trials; phase 2 used two injector pens)
• MDedge — Administration route: Subcutaneous injection (investigational fixed-dose combo pen in trials; phase 2 used two injector pens)
• Novo Nordisk company announcement 20 Dec 2024 — Trial data — REDEFINE 1: 68 wks, n=3,417: **22.7%** (trial-product estimand) / **20.4%** (treatment-policy estimand); 40.4% lost ≥25%. (Dec 2024)
• ECHEMI/Reuters-derived coverage — Trial data — REDEFINE 2: 68 wks, T2D population, n≈1,200: **15.7%** weight loss.
• Novo Nordisk press release via BioSpace/GlobeNewswire 23 Feb 2026 — Trial data — REDEFINE 4: 84 wks, open-label vs tirzepatide 15 mg, n=809: **23.0%** vs **25.5%** (efficacy estimand); 20.2% vs 23.6% (treatment-regimen estimand). (Feb 2026)
• Novo Nordisk ScienceHub — Trial data — REDEFINE 5: 68 wks, Japan/Taiwan, n=331: **18.4%** vs **11.9%** semaglutide (ETD −6.5 pp, p<0.0001).
• thelancet.com abstract — Trial data — REDEFINE 5: 68 wks, Japan/Taiwan, n=331: **18.4%** vs **11.9%** semaglutide (ETD −6.5 pp, p<0.0001).
• Patient Care Online — Regulatory status: **Investigational.** FDA NDA filed **Dec 2025**; decision expected **late 2026**. (Feb 2026)
• Drug Topics — Regulatory status: **Investigational.** FDA NDA filed **Dec 2025**; decision expected **late 2026**. (Feb 2026)
• BioSpace — - **REDEFINE 4** (n=809; 84 weeks; open-label head-to-head vs **tirzepatide 15 mg**): headline results **23 February 2026**. (February 2026)
• GlobeNewswire — - **REDEFINE 4** (n=809; 84 weeks; open-label head-to-head vs **tirzepatide 15 mg**): headline results **23 February 2026**. (February 2026)

Source URLs were not recorded for these references.